News & Analysis on Clinical Trial Services & Contract Research And Development
Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract. Most crystalline TKI drugs have pH-dependent solubility that affects their bioavailability in an oral dosage form.
This white paper outlines the challenges associated with pH-dependent solubility for oral TKI drugs and reviews how leveraging ASD formulation can help create more effective, patient-friendly drug products.
Paid for and in partnership with Lonza Small Molecules
Lonza’s innovative continuous flow technology and mini-monoplant approach are transforming early-phase drug development. How can they accelerate timelines and reduce costs?
Paid for and in partnership with Lonza Small Molecules
Applying AI-enabled route scouting services allows drug developers to avoid pitfalls that can typically occur in drug synthesis, speeding up drug substance IND.
Understanding pharmacokinetic behaviors ahead of later-stage development means making informed decisions earlier. This enhanced capability helps your drug development projects meet tight timelines and budget objectives.
Small Molecule drug development is something more and more ambitious emerging pharmaceutical companies are taking on from end to end. But this path can be fraught with risk.
For more product information visit Lonza Small Molecules.